Global Primary Myelofibrosis (PMF) market size is predicted to grow from US$ 164 million in 2025 to US$ 290 million in 2031; it is expected to grow at a CAGR of 10.0% from 2025 to 2031. Get Access Now!

Global Primary Myelofibrosis PMF Market Growth Status and Outlook 2025-2031

The global Primary Myelofibrosis (PMF) market size is predicted to grow from US$ 164 million in 2025 to US$ 290 million in 2031; it is expected to grow at a CAGR of 10.0% from 2025 to 2031. Primary myelofibrosis (MF) is a chronic blood cancer in which excessive scar tissue forms in the bone marrow and impairs its ability to produce normal blood cells. Researchers believe MF may be caused by abnormal blood stem cells in the bone marrow. The abnormal stem cells produce mature cells that grow quickly and take over the bone marrow, causing both fibrosis (scar tissue formation) and chronic inflammation. The statistic scope is primary myelofibrosis drug in this report. United States market for Primary Myelofibrosis (PMF) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031. China market for Primary Myelofibrosis (PMF) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031. Europe market for Primary Myelofibrosis (PMF) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031. Global key Primary Myelofibrosis (PMF) players cover GSK, AbbVie, Novartis, Celgene, Grunenthal, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024. Infinity Market Research newest research report, the Primary Myelofibrosis (PMF) Industry Forecast looks at past sales and reviews total world Primary Myelofibrosis (PMF) sales in 2024, providing a comprehensive analysis by region and market sector of projected Primary Myelofibrosis (PMF) sales for 2025 through 2031. With Primary Myelofibrosis (PMF) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Primary Myelofibrosis (PMF) industry. This Insight Report provides a comprehensive analysis of the global Primary Myelofibrosis (PMF) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Primary Myelofibrosis (PMF) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Primary Myelofibrosis (PMF) market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Primary Myelofibrosis (PMF) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Primary Myelofibrosis (PMF). This report presents a comprehensive overview, market shares, and growth opportunities of Primary Myelofibrosis (PMF) market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; JAK 1 &nbsp;&nbsp;&nbsp; JAK 2 &nbsp;&nbsp;&nbsp; Others Segmentation by Application: &nbsp;&nbsp;&nbsp; Adults &nbsp;&nbsp;&nbsp; Children This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; GSK &nbsp;&nbsp;&nbsp; AbbVie &nbsp;&nbsp;&nbsp; Novartis &nbsp;&nbsp;&nbsp; Celgene &nbsp;&nbsp;&nbsp; Grunenthal &nbsp;&nbsp;&nbsp; Incyte &nbsp;&nbsp;&nbsp; CTI BioPharma &nbsp;&nbsp;&nbsp; Bristol Myers Squibb &nbsp;&nbsp;&nbsp; Suzhou Zelgen Biopharmaceuticals Key Questions Addressed in this Report What is the 10-year outlook for the global Primary Myelofibrosis (PMF) market? What factors are driving Primary Myelofibrosis (PMF) market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do Primary Myelofibrosis (PMF) market opportunities vary by end market size? How does Primary Myelofibrosis (PMF) break out by Type, by Application?

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Primary Myelofibrosis (PMF) Annual Sales 2020-2031 &nbsp;2.1.2 World Current & Future Analysis for Primary Myelofibrosis (PMF) by Geographic Region, 2020, 2024 & 2031 &nbsp;2.1.3 World Current & Future Analysis for Primary Myelofibrosis (PMF) by Country/Region, 2020, 2024 & 2031 &nbsp;2.2 Primary Myelofibrosis (PMF) Segment by Type &nbsp;2.2.1 JAK 1 &nbsp;2.2.2 JAK 2 &nbsp;2.2.3 Others &nbsp;2.3 Primary Myelofibrosis (PMF) Sales by Type &nbsp;2.3.1 Global Primary Myelofibrosis (PMF) Sales Market Share by Type (2020-2025) &nbsp;2.3.2 Global Primary Myelofibrosis (PMF) Revenue and Market Share by Type (2020-2025) &nbsp;2.3.3 Global Primary Myelofibrosis (PMF) Sale Price by Type (2020-2025) &nbsp;2.4 Primary Myelofibrosis (PMF) Segment by Application &nbsp;2.4.1 Adults &nbsp;2.4.2 Children &nbsp;2.5 Primary Myelofibrosis (PMF) Sales by Application &nbsp;2.5.1 Global Primary Myelofibrosis (PMF) Sale Market Share by Application (2020-2025) &nbsp;2.5.2 Global Primary Myelofibrosis (PMF) Revenue and Market Share by Application (2020-2025) &nbsp;2.5.3 Global Primary Myelofibrosis (PMF) Sale Price by Application (2020-2025) 3 Global by Company &nbsp;3.1 Global Primary Myelofibrosis (PMF) Breakdown Data by Company &nbsp;3.1.1 Global Primary Myelofibrosis (PMF) Annual Sales by Company (2020-2025) &nbsp;3.1.2 Global Primary Myelofibrosis (PMF) Sales Market Share by Company (2020-2025) &nbsp;3.2 Global Primary Myelofibrosis (PMF) Annual Revenue by Company (2020-2025) &nbsp;3.2.1 Global Primary Myelofibrosis (PMF) Revenue by Company (2020-2025) &nbsp;3.2.2 Global Primary Myelofibrosis (PMF) Revenue Market Share by Company (2020-2025) &nbsp;3.3 Global Primary Myelofibrosis (PMF) Sale Price by Company &nbsp;3.4 Key Manufacturers Primary Myelofibrosis (PMF) Producing Area Distribution, Sales Area, Product Type &nbsp;3.4.1 Key Manufacturers Primary Myelofibrosis (PMF) Product Location Distribution &nbsp;3.4.2 Players Primary Myelofibrosis (PMF) Products Offered &nbsp;3.5 Market Concentration Rate Analysis &nbsp;3.5.1 Competition Landscape Analysis &nbsp;3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.6 New Products and Potential Entrants &nbsp;3.7 Market M&A Activity & Strategy 4 World Historic Review for Primary Myelofibrosis (PMF) by Geographic Region &nbsp;4.1 World Historic Primary Myelofibrosis (PMF) Market Size by Geographic Region (2020-2025) &nbsp;4.1.1 Global Primary Myelofibrosis (PMF) Annual Sales by Geographic Region (2020-2025) &nbsp;4.1.2 Global Primary Myelofibrosis (PMF) Annual Revenue by Geographic Region (2020-2025) &nbsp;4.2 World Historic Primary Myelofibrosis (PMF) Market Size by Country/Region (2020-2025) &nbsp;4.2.1 Global Primary Myelofibrosis (PMF) Annual Sales by Country/Region (2020-2025) &nbsp;4.2.2 Global Primary Myelofibrosis (PMF) Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas Primary Myelofibrosis (PMF) Sales Growth &nbsp;4.4 APAC Primary Myelofibrosis (PMF) Sales Growth &nbsp;4.5 Europe Primary Myelofibrosis (PMF) Sales Growth &nbsp;4.6 Middle East & Africa Primary Myelofibrosis (PMF) Sales Growth 5 Americas &nbsp;5.1 Americas Primary Myelofibrosis (PMF) Sales by Country &nbsp;5.1.1 Americas Primary Myelofibrosis (PMF) Sales by Country (2020-2025) &nbsp;5.1.2 Americas Primary Myelofibrosis (PMF) Revenue by Country (2020-2025) &nbsp;5.2 Americas Primary Myelofibrosis (PMF) Sales by Type (2020-2025) &nbsp;5.3 Americas Primary Myelofibrosis (PMF) Sales by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Primary Myelofibrosis (PMF) Sales by Region &nbsp;6.1.1 APAC Primary Myelofibrosis (PMF) Sales by Region (2020-2025) &nbsp;6.1.2 APAC Primary Myelofibrosis (PMF) Revenue by Region (2020-2025) &nbsp;6.2 APAC Primary Myelofibrosis (PMF) Sales by Type (2020-2025) &nbsp;6.3 APAC Primary Myelofibrosis (PMF) Sales by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia &nbsp;6.10 China Taiwan 7 Europe &nbsp;7.1 Europe Primary Myelofibrosis (PMF) by Country &nbsp;7.1.1 Europe Primary Myelofibrosis (PMF) Sales by Country (2020-2025) &nbsp;7.1.2 Europe Primary Myelofibrosis (PMF) Revenue by Country (2020-2025) &nbsp;7.2 Europe Primary Myelofibrosis (PMF) Sales by Type (2020-2025) &nbsp;7.3 Europe Primary Myelofibrosis (PMF) Sales by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Primary Myelofibrosis (PMF) by Country &nbsp;8.1.1 Middle East & Africa Primary Myelofibrosis (PMF) Sales by Country (2020-2025) &nbsp;8.1.2 Middle East & Africa Primary Myelofibrosis (PMF) Revenue by Country (2020-2025) &nbsp;8.2 Middle East & Africa Primary Myelofibrosis (PMF) Sales by Type (2020-2025) &nbsp;8.3 Middle East & Africa Primary Myelofibrosis (PMF) Sales by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Manufacturing Cost Structure Analysis &nbsp;10.1 Raw Material and Suppliers &nbsp;10.2 Manufacturing Cost Structure Analysis of Primary Myelofibrosis (PMF) &nbsp;10.3 Manufacturing Process Analysis of Primary Myelofibrosis (PMF) &nbsp;10.4 Industry Chain Structure of Primary Myelofibrosis (PMF) 11 Marketing, Distributors and Customer &nbsp;11.1 Sales Channel &nbsp;11.1.1 Direct Channels &nbsp;11.1.2 Indirect Channels &nbsp;11.2 Primary Myelofibrosis (PMF) Distributors &nbsp;11.3 Primary Myelofibrosis (PMF) Customer 12 World Forecast Review for Primary Myelofibrosis (PMF) by Geographic Region &nbsp;12.1 Global Primary Myelofibrosis (PMF) Market Size Forecast by Region &nbsp;12.1.1 Global Primary Myelofibrosis (PMF) Forecast by Region (2026-2031) &nbsp;12.1.2 Global Primary Myelofibrosis (PMF) Annual Revenue Forecast by Region (2026-2031) &nbsp;12.2 Americas Forecast by Country (2026-2031) &nbsp;12.3 APAC Forecast by Region (2026-2031) &nbsp;12.4 Europe Forecast by Country (2026-2031) &nbsp;12.5 Middle East & Africa Forecast by Country (2026-2031) &nbsp;12.6 Global Primary Myelofibrosis (PMF) Forecast by Type (2026-2031) &nbsp;12.7 Global Primary Myelofibrosis (PMF) Forecast by Application (2026-2031) 13 Key Players Analysis &nbsp;13.1 GSK &nbsp;13.1.1 GSK Company Information &nbsp;13.1.2 GSK Primary Myelofibrosis (PMF) Product Portfolios and Specifications &nbsp;13.1.3 GSK Primary Myelofibrosis (PMF) Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.1.4 GSK Main Business Overview &nbsp;13.1.5 GSK Latest Developments &nbsp;13.2 AbbVie &nbsp;13.2.1 AbbVie Company Information &nbsp;13.2.2 AbbVie Primary Myelofibrosis (PMF) Product Portfolios and Specifications &nbsp;13.2.3 AbbVie Primary Myelofibrosis (PMF) Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.2.4 AbbVie Main Business Overview &nbsp;13.2.5 AbbVie Latest Developments &nbsp;13.3 Novartis &nbsp;13.3.1 Novartis Company Information &nbsp;13.3.2 Novartis Primary Myelofibrosis (PMF) Product Portfolios and Specifications &nbsp;13.3.3 Novartis Primary Myelofibrosis (PMF) Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.3.4 Novartis Main Business Overview &nbsp;13.3.5 Novartis Latest Developments &nbsp;13.4 Celgene &nbsp;13.4.1 Celgene Company Information &nbsp;13.4.2 Celgene Primary Myelofibrosis (PMF) Product Portfolios and Specifications &nbsp;13.4.3 Celgene Primary Myelofibrosis (PMF) Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.4.4 Celgene Main Business Overview &nbsp;13.4.5 Celgene Latest Developments &nbsp;13.5 Grunenthal &nbsp;13.5.1 Grunenthal Company Information &nbsp;13.5.2 Grunenthal Primary Myelofibrosis (PMF) Product Portfolios and Specifications &nbsp;13.5.3 Grunenthal Primary Myelofibrosis (PMF) Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.5.4 Grunenthal Main Business Overview &nbsp;13.5.5 Grunenthal Latest Developments &nbsp;13.6 Incyte &nbsp;13.6.1 Incyte Company Information &nbsp;13.6.2 Incyte Primary Myelofibrosis (PMF) Product Portfolios and Specifications &nbsp;13.6.3 Incyte Primary Myelofibrosis (PMF) Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.6.4 Incyte Main Business Overview &nbsp;13.6.5 Incyte Latest Developments &nbsp;13.7 CTI BioPharma &nbsp;13.7.1 CTI BioPharma Company Information &nbsp;13.7.2 CTI BioPharma Primary Myelofibrosis (PMF) Product Portfolios and Specifications &nbsp;13.7.3 CTI BioPharma Primary Myelofibrosis (PMF) Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.7.4 CTI BioPharma Main Business Overview &nbsp;13.7.5 CTI BioPharma Latest Developments &nbsp;13.8 Bristol Myers Squibb &nbsp;13.8.1 Bristol Myers Squibb Company Information &nbsp;13.8.2 Bristol Myers Squibb Primary Myelofibrosis (PMF) Product Portfolios and Specifications &nbsp;13.8.3 Bristol Myers Squibb Primary Myelofibrosis (PMF) Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.8.4 Bristol Myers Squibb Main Business Overview &nbsp;13.8.5 Bristol Myers Squibb Latest Developments &nbsp;13.9 Suzhou Zelgen Biopharmaceuticals &nbsp;13.9.1 Suzhou Zelgen Biopharmaceuticals Company Information &nbsp;13.9.2 Suzhou Zelgen Biopharmaceuticals Primary Myelofibrosis (PMF) Product Portfolios and Specifications &nbsp;13.9.3 Suzhou Zelgen Biopharmaceuticals Primary Myelofibrosis (PMF) Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.9.4 Suzhou Zelgen Biopharmaceuticals Main Business Overview &nbsp;13.9.5 Suzhou Zelgen Biopharmaceuticals Latest Developments 14 Research Findings and Conclusion

Report	Global Primary Myelofibrosis (PMF) Market Growth 2025-2031
Selected License	Multi ID: LPI35900

Buyer Information

Order Summary